Guardion Health Sciences recently announced it has completed is registration with the U.S. Securities and Exchange Commission and is now a public reporting company.
In 2017, the specialty health sciences company reportedly plans to focus on age-related eye disease and vision performance, continuing to address the growing need for early detection and intervention for age-related macular degeneration (AMD) and other retinal diseases. Additionally, Guardion reportedly plans to begin evaluating potential acquisitions of synergistic and "value-added" technologies.
Click here to read the full press release.
Source: Guardion Health Sciences